LAKE FOREST, Calif.,
Sept. 8, 2014 /PRNewswire/
-- Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading
provider of advanced cryogenic logistics solutions for the life
sciences industry, announced today the appointment of Curt Kole to the new role of VP, Strategic
Business Development. Cryoport's new business development personnel
will support the Company's rapid development and integration of
large-scale corporate clients. In addition to securing new business
sectors and major accounts for Cryoport, this new function will be
responsible for the management of many key partnerships for the
Company.
In addition, the Company is accelerating the expansion of its
direct sales representation in key areas of the East Coast. This
initiative is meant to capitalize on the growing market demand for
leading edge cryogenic logistics solutions for the life sciences
industry and to target additional major life sciences companies
that would benefit from Cryoport's comprehensive range of
solutions.
Jerrell Shelton, Chief Executive
Officer of Cryoport, stated, "Cryoport's sales organization has
extensive knowledge in the cold chain logistics market. This
combined with our wide network of key relationships in the life
science arena will advance our growth and broaden our customer
base. This is the 'age of biology' and Cryoport plays a very
important role, if not a unique role, in the biosciences."
Mr. Shelton continued, "We are pleased to announce the promotion
of Curt Kole to VP of Strategic
Business Development. It is an important new role within Cryoport's
overall sales strategy. Curt's 17 years of experience in the cold
chain industry, including more than 3.5 years with Cryoport where
he most recently served as Sales Director, will serve our business
expansion efforts well. To date, we have also added several Sales
Directors experienced in the cold chain logistics industry to our
team, in support of our sales growth initiatives. Given their
extensive backgrounds, we are expecting near term results.
"Having completed multiple quarters of notable growth, we are
pursuing parallel expansion programs to address specific market
sectors, including IVF and animal husbandry. As a global company,
we will expand our presence in Europe, Latin
America, and Asia. Looking
forward, we plan to continue to expand our marketing and business
development efforts as well as adding sales personnel as our market
grows," concluded Mr. Shelton.
About Cryoport, Inc.
Cryoport provides leading edge cryogenic logistics solutions to
the life sciences industry through the combination of purpose-built
proprietary packaging, advanced information technology and highly
skilled logistics expertise which manages the entire cold chain
logistics process. Cryoport Express® liquid nitrogen dry
vapor shippers are validated to maintain a constant -150 degrees C
temperature for a 10-plus day dynamic shipment duration, and its
Cryoportalâ„¢ Logistics Management Platform assists in managing the
entire logistics process, including initial order input, document
preparation, customs clearance, courier management, shipment
tracking, issue resolution, and delivery. Cryoport's total turnkey
logistics solutions offer reliability, cost effectiveness, and
convenience, while the use of recyclable and reusable components
provides a "green" and environmentally friendly solution. Cryoport
service options include recording the "chain of condition" and
"chain of custody" for all shipments thereby meeting the exacting
requirements for scientific work and for regulatory purposes. For
more information visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this press release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2014. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise, any forward-looking statements in this press
release.
Cryoport Contacts:
Todd
Fromer / Garth Russell
tfromer@kcsa.com / grussell@kcsa.com
P: 1-212-682-6300
SOURCE Cryoport, Inc.